Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 5/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968352 | 0.79 | GRM4 (0.32) | GRM4HTR1AHTR7HTR6 | |
| SCHEMBL103662 | 0.79 | GPR84 (0.33) | GRM4HRH4 | |
| SCHEMBL204111 | 0.76 | — | — | |
| SCHEMBL16759891 | 0.76 | HTR1A (0.31) | HTR1AHTR7HTR6 | |
| SCHEMBL2995564 | 0.76 | DPP4 (0.36) | GRM4HTR1A | |
| SCHEMBL1426962 | 0.76 | GRM4 (0.33) | GRM4 | |
| SCHEMBL9172776 | 0.74 | DPP4 (0.35) | GRM4HTR1A | |
| SCHEMBL3963364 | 0.72 | NOTUM (0.33) | — | |
| SCHEMBL14087040 | 0.72 | GRIN2D (0.36) | — | |
| SCHEMBL103967 | 0.71 | NOS1 (0.44) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542297-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11530237-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220150-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220213137-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20200392177-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10577390-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| WO-2016061527-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530237-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, ADRA1A | GRM4 91/4885HTR1A 199/4885HTR7 666/4885 |
| US-10577390-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, GRIN2B | GRM4 90/4885HTR1A 189/4885HTR7 637/4885 |
| US-20220220150-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | GRM4 91/4885HTR1A 198/4885HTR7 657/4885 |
| US-20200392177-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | GRM4 91/4885HTR1A 199/4885HTR7 666/4885 |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | GRM4 91/4885HTR1A 194/4885HTR7 673/4885 |
| US-11542297-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, ADRA1A | GRM4 91/4885HTR1A 198/4885HTR7 657/4885 |
| US-20220213137-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | GRM4 90/4885HTR1A 189/4885HTR7 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.